Oxervate Patient Enrollment Form

Oxervate Patient Enrollment Form - 1 To begin the process you simply sign the OXERVATE prescription enrollment form at your doctor s ofice Once insurance coverage has been determined you can expect a welcome call from Domp CONNECT to Care within 24 hours after they receive the enrollment form from your doctor Please have your insurance prescription card handy during the call

DC2C Enrollment Form OXERVATE prescription form and patient enrollment Download PDF Appeal Letter Guide Insurance appeals overview and sample letter Download PDF HCP DC2C Roadmap HCP process for the access program Download PDF HCP DC2C Overview List of access program resources Download PDF Important Safety Information

Oxervate Patient Enrollment Form

Oxervate Patient Enrollment Form

OXERVATE® PATIENT ENROLLMENT FORM OXERVATE® PATIENT ENROLLMENT FORM INSTRUCTIONS: Complete all pages of this form for each new prescription. Please print. Please fax completed form to Dompé CONNECT to Care at 1-855-263-1775, phone 1-877-422-4412. Please provide copies of front and back of all insurance cards. DC2C PATIENT INFORMATION

OXERVATE PATIENT ENROLLMENT FORM INSTRUCTIONS Complete all pages of this form for each new prescription Please print Please fax completed form to Domp CONNECT to Care at 1 855 263 1775 phone 1 877 422 4412 Please provide copies of front and back of all insurance cards PATIENT INFORMATION Preferred Phone Alternative Phone Best Time to Call

Access Resources OXERVATE Cenegermin Bkbj

1 Fax completed enrollment form on the patient s behalf DOWNLOAD FORM OR 2 Use the iAssist digital portal to complete enrollment GO TO iASSIST Remember Patient Authorization section of enrollment form must be completed Questions Contact Domp CONNECT to Care Phone 1 877 422 4412 Fax 1 855 263 1775

Fillable Care And Treatment Enrollment Form Printable Pdf Download

In 2 clinical trials of patients with neurotrophic keratitis a total of 101 patients received cenegermin bkbj eye drops at 20 mcg mL at a frequency of 6 times daily in the affected eye s for a duration of 8 weeks The mean age of the population was 61 to 65 years of age 18 to 95 The most common adverse reaction in clinical trials that

Span Class Result Type

Cenegermin bkbj the active ingredient in OXERVATE is a recombinant form of human nerve growth factor NGF that supports corneal innervation and integrity 1 3 6 7 See how NGF Works Efficacy Safety The efficacy and safety of OXERVATE were established in the largest clinical trial program conducted in patients with NK 1

Xtandi Support Solutions Patient Enrollment Form Enrollment Form

Completed enrollment form serves as the OXERVATE prescription and enrolls your patient into Domp CONNECT to Care DC2C Note Patient Authorization section of enrollment Fax form must be completed Fax completed 24 HOURS confirmation enrollment form to DC2C on your patient s behalf

this form is Protected Health Information under HIPAA. URGENT MEMBER INFORMATION LAST NAME: FIRST NAME: ... CITY: STATE: ZIP CODE: PATIENT INSURANCE ID NUMBER: MALE FEMALE HEIGHT (IN/CM): _____ WEIGHT (LB/KG): _____ ALLERGIES: _____ IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH ...

Span Class Result Type

Dompe Connect to Care Oxervate cenegermin BKBJ ophthalmic solution CONTACT INFO Address Phone 1 877 422 4412 Provider Phone Fax

Oxervate Patient Enrollment Form

Completed enrollment form serves as the OXERVATE prescription and enrolls your patient into Domp CONNECT to Care DC2C Note Patient Authorization section of enrollment Fax form must be completed Fax completed 24 HOURS confirmation enrollment form to DC2C on your patient s behalf

DC2C Enrollment Form OXERVATE prescription form and patient enrollment Download PDF Appeal Letter Guide Insurance appeals overview and sample letter Download PDF HCP DC2C Roadmap HCP process for the access program Download PDF HCP DC2C Overview List of access program resources Download PDF Important Safety Information

A Look At Oxervate And Treatment For Neurotrophic Keratitis EyeWorld